New Jersey: Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. Glenmark’s Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue®2 Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630].
According to IQVIA® sales data for the 12-month period ending April 2026, the ProvayBlue® Injection, 50 mg/10 mL (5 mg/mL) market3 achieved annual sales of approximately $19.0 million*.
Marc Kikuchi, President & Business Head, North America said, “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.”
